RU2330855C2 - Новые трициклические производные, как антагонисты ltd4 - Google Patents
Новые трициклические производные, как антагонисты ltd4 Download PDFInfo
- Publication number
- RU2330855C2 RU2330855C2 RU2005118757/04A RU2005118757A RU2330855C2 RU 2330855 C2 RU2330855 C2 RU 2330855C2 RU 2005118757/04 A RU2005118757/04 A RU 2005118757/04A RU 2005118757 A RU2005118757 A RU 2005118757A RU 2330855 C2 RU2330855 C2 RU 2330855C2
- Authority
- RU
- Russia
- Prior art keywords
- dihydro
- benzoxepino
- thio
- difluoroquinolin
- pyridin
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000005843 halogen group Chemical group 0.000 claims abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 3
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 claims abstract 3
- 208000026935 allergic disease Diseases 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims abstract 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 9
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 9
- -1 2-cyclopropylpropyl Chemical group 0.000 claims 7
- 235000019260 propionic acid Nutrition 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 claims 4
- 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 230000008485 antagonism Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039094 Rhinitis perennial Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 208000002365 Viral Bronchiolitis Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000022719 perennial allergic rhinitis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- BPNOGBPLSZHUGE-UHFFFAOYSA-N 2-[1-[[9-[(6,7-difluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanylmethyl]cyclopropyl]acetic acid Chemical compound C12=CC=CN=C2COC2=CC=C(OCC=3N=C4C=C(F)C(F)=CC4=CC=3)C=C2C1SCC1(CC(=O)O)CC1 BPNOGBPLSZHUGE-UHFFFAOYSA-N 0.000 claims 1
- KBNWIWYCOPKHBC-UHFFFAOYSA-N 2-[1-[[9-[(6,7-difluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[4,3-b]pyridin-11-yl]sulfanylmethyl]cyclopropyl]acetic acid Chemical compound C12=CC(OCC=3N=C4C=C(F)C(F)=CC4=CC=3)=CC=C2OCC2=CC=CN=C2C1SCC1(CC(=O)O)CC1 KBNWIWYCOPKHBC-UHFFFAOYSA-N 0.000 claims 1
- GYYISXLMDPGNDD-ZZXKWVIFSA-N 2-[1-[[9-[(e)-2-(6,7-difluoroquinolin-2-yl)ethenyl]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanylmethyl]cyclopropyl]acetic acid Chemical compound C12=CC=CN=C2COC2=CC=C(\C=C\C=3N=C4C=C(F)C(F)=CC4=CC=3)C=C2C1SCC1(CC(=O)O)CC1 GYYISXLMDPGNDD-ZZXKWVIFSA-N 0.000 claims 1
- PNOCLWDEJRKWDF-UHFFFAOYSA-N 2-[[9-[(6,7-difluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanyl]acetic acid Chemical compound C1=C2C(SCC(=O)O)C3=CC=CN=C3COC2=CC=C1OCC1=CC=C(C=C(F)C(F)=C2)C2=N1 PNOCLWDEJRKWDF-UHFFFAOYSA-N 0.000 claims 1
- ROJDXFZAEPIOCC-UHFFFAOYSA-N 2-[[9-[(7-chloro-6-fluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanyl]acetic acid Chemical compound C1=C2C(SCC(=O)O)C3=CC=CN=C3COC2=CC=C1OCC1=CC=C(C=C(F)C(Cl)=C2)C2=N1 ROJDXFZAEPIOCC-UHFFFAOYSA-N 0.000 claims 1
- ZMQFCIHNHAQNAQ-ZZXKWVIFSA-N 2-[[9-[(e)-2-(6,7-difluoroquinolin-2-yl)ethenyl]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanyl]acetic acid Chemical compound O1CC2=NC=CC=C2C(SCC(=O)O)C2=CC(\C=C\C=3N=C4C=C(F)C(F)=CC4=CC=3)=CC=C21 ZMQFCIHNHAQNAQ-ZZXKWVIFSA-N 0.000 claims 1
- MHABCZSIDVZHOQ-UHFFFAOYSA-N 3-[[9-[(6,7-difluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanyl]-2,2-dimethylpropanoic acid Chemical compound C1=C2C(SCC(C)(C)C(O)=O)C3=CC=CN=C3COC2=CC=C1OCC1=CC=C(C=C(F)C(F)=C2)C2=N1 MHABCZSIDVZHOQ-UHFFFAOYSA-N 0.000 claims 1
- OLKUFZKAFAHFAP-UHFFFAOYSA-N 3-[[9-[(6,7-difluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanyl]-3-methylbutanoic acid Chemical compound C1=C2C(SC(C)(CC(O)=O)C)C3=CC=CN=C3COC2=CC=C1OCC1=CC=C(C=C(F)C(F)=C2)C2=N1 OLKUFZKAFAHFAP-UHFFFAOYSA-N 0.000 claims 1
- WUUCIVNJEOVHOV-UHFFFAOYSA-N 3-[[9-[(6,7-difluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanyl]propanoic acid Chemical compound C1=C2C(SCCC(=O)O)C3=CC=CN=C3COC2=CC=C1OCC1=CC=C(C=C(F)C(F)=C2)C2=N1 WUUCIVNJEOVHOV-UHFFFAOYSA-N 0.000 claims 1
- WWUVRNPLHSRXHV-UHFFFAOYSA-N 3-[[9-[(6,7-difluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[4,3-b]pyridin-11-yl]sulfanyl]propanoic acid Chemical compound O1CC2=CC=CN=C2C(SCCC(=O)O)C2=CC(OCC=3N=C4C=C(F)C(F)=CC4=CC=3)=CC=C21 WWUVRNPLHSRXHV-UHFFFAOYSA-N 0.000 claims 1
- QPNKWUKRPUIIAQ-UHFFFAOYSA-N 3-[[9-[(7-chloro-6-fluoroquinolin-2-yl)methoxy]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanyl]propanoic acid Chemical compound C1=C2C(SCCC(=O)O)C3=CC=CN=C3COC2=CC=C1OCC1=CC=C(C=C(F)C(Cl)=C2)C2=N1 QPNKWUKRPUIIAQ-UHFFFAOYSA-N 0.000 claims 1
- XBQBKXHXJXVKPN-ZZXKWVIFSA-N 3-[[9-[(e)-2-(6,7-difluoroquinolin-2-yl)ethenyl]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridin-11-yl]sulfanyl]propanoic acid Chemical compound O1CC2=NC=CC=C2C(SCCC(=O)O)C2=CC(\C=C\C=3N=C4C=C(F)C(F)=CC4=CC=3)=CC=C21 XBQBKXHXJXVKPN-ZZXKWVIFSA-N 0.000 claims 1
- BCTLZWXWOKDEJF-ZZXKWVIFSA-N 3-[[9-[(e)-2-(6,7-difluoroquinolin-2-yl)ethenyl]-5,11-dihydro-[1]benzoxepino[4,3-b]pyridin-11-yl]sulfanyl]propanoic acid Chemical compound O1CC2=CC=CN=C2C(SCCC(=O)O)C2=CC(\C=C\C=3N=C4C=C(F)C(F)=CC4=CC=3)=CC=C21 BCTLZWXWOKDEJF-ZZXKWVIFSA-N 0.000 claims 1
- IOUGOEHZTBRJIY-UHFFFAOYSA-N 9-[(6,7-difluoroquinolin-2-yl)methoxy]-11-[2-(2h-tetrazol-5-yl)ethylsulfanyl]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridine Chemical compound N1=C2C=C(F)C(F)=CC2=CC=C1COC(C=C12)=CC=C1OCC1=NC=CC=C1C2SCCC1=NN=NN1 IOUGOEHZTBRJIY-UHFFFAOYSA-N 0.000 claims 1
- PMSGXRLYMCEJQU-ZZXKWVIFSA-N 9-[(e)-2-(6,7-difluoroquinolin-2-yl)ethenyl]-11-[2-(2h-tetrazol-5-yl)ethylsulfanyl]-5,11-dihydro-[1]benzoxepino[3,4-b]pyridine Chemical compound N1=C2C=C(F)C(F)=CC2=CC=C1\C=C\C(C=C12)=CC=C1OCC1=NC=CC=C1C2SCCC1=NN=NN1 PMSGXRLYMCEJQU-ZZXKWVIFSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polyurethanes Or Polyureas (AREA)
- Hydrogenated Pyridines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200202590A ES2211315B1 (es) | 2002-11-12 | 2002-11-12 | Nuevos compuestos triciclicos. |
| ES200202590 | 2002-11-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005118757A RU2005118757A (ru) | 2006-02-27 |
| RU2330855C2 true RU2330855C2 (ru) | 2008-08-10 |
Family
ID=32309630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005118757/04A RU2330855C2 (ru) | 2002-11-12 | 2003-11-11 | Новые трициклические производные, как антагонисты ltd4 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7557212B2 (enExample) |
| EP (1) | EP1560834B1 (enExample) |
| JP (1) | JP2006508116A (enExample) |
| KR (1) | KR20050074605A (enExample) |
| CN (1) | CN100379742C (enExample) |
| AT (1) | ATE399170T1 (enExample) |
| AU (1) | AU2003288032A1 (enExample) |
| BR (1) | BR0315462A (enExample) |
| CA (1) | CA2505491A1 (enExample) |
| CO (1) | CO5700775A2 (enExample) |
| DE (1) | DE60321810D1 (enExample) |
| EC (1) | ECSP055844A (enExample) |
| ES (2) | ES2211315B1 (enExample) |
| MX (1) | MXPA05005017A (enExample) |
| NO (1) | NO20052858L (enExample) |
| RU (1) | RU2330855C2 (enExample) |
| UA (1) | UA80996C2 (enExample) |
| WO (1) | WO2004043966A1 (enExample) |
| ZA (1) | ZA200503806B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| AU2005247105B2 (en) | 2004-05-31 | 2010-11-11 | Laboratorios Almirall, S.A. | Combinations comprising antimuscarinic agents and corticosteroids |
| DK1896421T3 (da) | 2005-06-23 | 2012-01-09 | Merck Sharp & Dohme | Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET |
| CA2624656A1 (en) * | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| CA2842881A1 (en) | 2011-07-26 | 2013-04-11 | Rajendrasinh RATHOD | Cysteinyl leukotriene antagonists |
| JP2019081709A (ja) * | 2016-03-18 | 2019-05-30 | 石原産業株式会社 | 有害生物防除剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0685478A1 (en) * | 1993-02-16 | 1995-12-06 | Ube Industries, Ltd. | Quinoline derivative |
| RU2000116548A (ru) * | 1997-11-25 | 2002-08-10 | Шеринг Корпорейшн | Антагонисты тромбинового рецептора |
| EP1254897A1 (en) * | 1999-12-28 | 2002-11-06 | Ube Industries, Ltd. | Tricyclic compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341044C (en) * | 1988-04-28 | 2000-07-04 | Frank J. Villani | Benzopyrido piperidine, piperidylidene and peperazine compounds, compositions, methods of manufacture and methods of use |
| NZ234883A (en) * | 1989-08-22 | 1995-01-27 | Merck Frosst Canada Inc | Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof |
| ATE266025T1 (de) * | 1997-11-25 | 2004-05-15 | Schering Corp | Thrombin-rezeptor antagonisten |
| JP2006151809A (ja) * | 2002-12-26 | 2006-06-15 | Ube Ind Ltd | ベンゾシクロヘプタピリジン化合物 |
-
2002
- 2002-11-12 ES ES200202590A patent/ES2211315B1/es not_active Expired - Fee Related
-
2003
- 2003-11-11 MX MXPA05005017A patent/MXPA05005017A/es not_active Application Discontinuation
- 2003-11-11 KR KR1020057008474A patent/KR20050074605A/ko not_active Withdrawn
- 2003-11-11 ES ES03779886T patent/ES2306906T3/es not_active Expired - Lifetime
- 2003-11-11 WO PCT/EP2003/012581 patent/WO2004043966A1/en not_active Ceased
- 2003-11-11 BR BR0315462-9A patent/BR0315462A/pt not_active IP Right Cessation
- 2003-11-11 RU RU2005118757/04A patent/RU2330855C2/ru not_active IP Right Cessation
- 2003-11-11 EP EP03779886A patent/EP1560834B1/en not_active Expired - Lifetime
- 2003-11-11 AT AT03779886T patent/ATE399170T1/de not_active IP Right Cessation
- 2003-11-11 AU AU2003288032A patent/AU2003288032A1/en not_active Abandoned
- 2003-11-11 CA CA002505491A patent/CA2505491A1/en not_active Abandoned
- 2003-11-11 DE DE60321810T patent/DE60321810D1/de not_active Expired - Lifetime
- 2003-11-11 UA UAA200505509A patent/UA80996C2/uk unknown
- 2003-11-11 JP JP2004550982A patent/JP2006508116A/ja active Pending
- 2003-11-11 CN CNB2003801085261A patent/CN100379742C/zh not_active Expired - Fee Related
- 2003-11-11 US US10/534,487 patent/US7557212B2/en not_active Expired - Fee Related
-
2005
- 2005-05-11 ZA ZA200503806A patent/ZA200503806B/en unknown
- 2005-06-09 EC EC2005005844A patent/ECSP055844A/es unknown
- 2005-06-10 CO CO05056627A patent/CO5700775A2/es unknown
- 2005-06-13 NO NO20052858A patent/NO20052858L/no not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0685478A1 (en) * | 1993-02-16 | 1995-12-06 | Ube Industries, Ltd. | Quinoline derivative |
| RU2000116548A (ru) * | 1997-11-25 | 2002-08-10 | Шеринг Корпорейшн | Антагонисты тромбинового рецептора |
| EP1254897A1 (en) * | 1999-12-28 | 2002-11-06 | Ube Industries, Ltd. | Tricyclic compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100379742C (zh) | 2008-04-09 |
| CN1735618A (zh) | 2006-02-15 |
| CA2505491A1 (en) | 2004-05-27 |
| US7557212B2 (en) | 2009-07-07 |
| ECSP055844A (es) | 2005-09-20 |
| US20060116363A1 (en) | 2006-06-01 |
| RU2005118757A (ru) | 2006-02-27 |
| CO5700775A2 (es) | 2006-11-30 |
| EP1560834A1 (en) | 2005-08-10 |
| ZA200503806B (en) | 2006-08-30 |
| ES2211315A1 (es) | 2004-07-01 |
| NO20052858D0 (no) | 2005-06-13 |
| MXPA05005017A (es) | 2005-08-03 |
| ATE399170T1 (de) | 2008-07-15 |
| AU2003288032A1 (en) | 2004-06-03 |
| JP2006508116A (ja) | 2006-03-09 |
| ES2211315B1 (es) | 2005-10-16 |
| KR20050074605A (ko) | 2005-07-18 |
| EP1560834B1 (en) | 2008-06-25 |
| WO2004043966A1 (en) | 2004-05-27 |
| ES2306906T3 (es) | 2008-11-16 |
| DE60321810D1 (de) | 2008-08-07 |
| BR0315462A (pt) | 2005-08-23 |
| UA80996C2 (en) | 2007-11-26 |
| NO20052858L (no) | 2005-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2330855C2 (ru) | Новые трициклические производные, как антагонисты ltd4 | |
| JP7037679B2 (ja) | 新規の二環式ブロモドメイン阻害剤 | |
| ES2791401T3 (es) | Compuestos tricíclicos y sus usos en medicina | |
| AU2009298008B2 (en) | Pyrazolo pyridine derivatives as NADPH Oxidase inhibitors | |
| RU2168511C2 (ru) | Производные пиридазинохинолина | |
| AU2018212438C1 (en) | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | |
| CN111712496B (zh) | 作为溴结构域蛋白质抑制剂的化合物和组合物 | |
| US5420138A (en) | Bicyclic pyridines which are angiotensin II inhibitors | |
| AU2006226084B2 (en) | 2,3-substituted fused pyrimidin-4(3H)-ones as VR1 antagonists | |
| JP2000502723A (ja) | 置換された６，５―ヘテロ―二環式誘導体 | |
| KR20150028798A (ko) | 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 하이드록사메이트 유도체 및 이를 포함하는 약제학적 조성물 | |
| KR20180119582A (ko) | 라이실 옥시다제의 인돌 및 아자인돌 할로알릴아민 유도체 억제제 및 이의 용도 | |
| CN102227221A (zh) | 包含hsp90抑制剂和mtor抑制剂的药物组合 | |
| JP2021513551A (ja) | 複素環式化合物、その応用及びそれを含有する医薬組成物 | |
| RU2012142194A (ru) | Ингибиторы катехол-о-метилтрансферазы и их применение при лечении психотических расстройств | |
| AU2009295230A1 (en) | Indole derivatives as CRTH2 receptor antagonists | |
| AU2009267111A1 (en) | Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | |
| CN111320624A (zh) | 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途 | |
| JP2002523415A (ja) | 新規な化合物 | |
| PT1534707E (pt) | Derivados de 2,4-di-hidro-pirrolo(3,4-b)-quinolin-9-ona substituídos, úteis como inibidores da fosfodiesterase | |
| AU2004263297A1 (en) | Substituted imidazopyrimidines for the prevention and treatment of cancer | |
| JP2006508116A5 (enExample) | ||
| JP2004508330A5 (enExample) | ||
| PT1648897E (pt) | N-[3-(3-substituídos-pirazolo[1,5a]pirimidin-7-il]fenil]- sulfonamidas e composições e métodos a elas relacionados | |
| JP2008503466A (ja) | 勃起不全または尿失禁を治療または予防する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20081112 |